Ocular Therapeutix, Inc. $OCUL Position Reduced by Vontobel Holding Ltd.

Vontobel Holding Ltd. lowered its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 90.5% in the third quarter, HoldingsChannel.com reports. The fund owned 10,628 shares of the biopharmaceutical company’s stock after selling 100,740 shares during the quarter. Vontobel Holding Ltd.’s holdings in Ocular Therapeutix were worth $82,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Ocular Therapeutix in the 2nd quarter valued at about $190,278,000. Summer Road LLC lifted its stake in Ocular Therapeutix by 6.9% in the 1st quarter. Summer Road LLC now owns 11,879,825 shares of the biopharmaceutical company’s stock valued at $100,622,000 after purchasing an additional 771,270 shares during the last quarter. Octagon Capital Advisors LP lifted its stake in Ocular Therapeutix by 20.7% in the 1st quarter. Octagon Capital Advisors LP now owns 3,166,600 shares of the biopharmaceutical company’s stock valued at $26,821,000 after purchasing an additional 543,000 shares during the last quarter. Commodore Capital LP bought a new position in Ocular Therapeutix during the first quarter worth about $21,810,000. Finally, Squarepoint Ops LLC increased its position in Ocular Therapeutix by 44.4% during the second quarter. Squarepoint Ops LLC now owns 1,415,913 shares of the biopharmaceutical company’s stock worth $13,904,000 after buying an additional 435,156 shares during the last quarter. Institutional investors own 59.21% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on OCUL shares. Zacks Research upgraded Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Thursday, October 15th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, September 29th. Wall Street Zen raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $18.00 price target on shares of Ocular Therapeutix in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.86.

Ocular Therapeutix Stock Performance

Shares of NASDAQ:OCUL opened at $6.61 on Friday. Ocular Therapeutix, Inc. has a 1 year low of $6.00 and a 1 year high of $16.44. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.10 and a quick ratio of 13.03. The business’s 50 day simple moving average is $9.29 and its 200 day simple moving average is $9.18.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.05. The firm had revenue of $13.47 million during the quarter, compared to analysts’ expectations of $13.20 million. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%. The company’s quarterly revenue was down .1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.39) EPS. On average, sell-side analysts anticipate that Ocular Therapeutix, Inc. will post -1.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Todd Anderman sold 11,984 shares of the firm’s stock in a transaction on Thursday, October 8th. The stock was sold at an average price of $7.29, for a total value of $87,363.36. Following the transaction, the insider owned 140,484 shares in the company, valued at approximately $1,024,128.36. This trade represents a 7.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jeffrey Heier sold 10,869 shares of the business’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $7.05, for a total value of $76,626.45. Following the completion of the transaction, the insider directly owned 307,457 shares of the company’s stock, valued at approximately $2,167,571.85. This trade represents a 3.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 62,720 shares of company stock valued at $556,247. Company insiders own 3.10% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc (NASDAQ:OCUL) is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based drug-delivery technology to provide sustained or controlled release of medicines in ophthalmic applications.

Its commercial products include Dextenza, a dexamethasone ophthalmic insert used to treat ocular inflammation and itching following ophthalmic surgery, and Yutiq, a fluocinolone acetonide intravitreal implant indicated for the treatment of chronic noninfectious posterior uveitis.